Cargando…

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast prolifer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comont, Thibault, Treiner, Emmanuel, Vergez, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620222/ https://www.ncbi.nlm.nih.gov/pubmed/34829329 http://dx.doi.org/10.3390/diagnostics11111982

Ejemplares similares

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
por: Zhang, Xiaoying, et al.
Publicado: (2023)

S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES
por: Dussiau, Charles, et al.
Publicado: (2023)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Immune Checkpoints in Solid Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2023)

Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
por: Park, Hee Sue, et al.
Publicado: (2017)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
por: Sochacki, Andrew L, et al.
Publicado: (2016)

Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review
por: Lynch, Olivia F., et al.
Publicado: (2022)

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
por: Chanias, Ioannis, et al.
Publicado: (2021)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

The microenvironment in myelodysplastic syndromes: From concept to therapeutic target
por: Raaijmakers, Marc H.G.P.
Publicado: (2018)

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
por: Chokr, Nora, et al.
Publicado: (2018)

Myelodysplastic syndrome from theoretical review to clinical application view
por: Mohammad, Amrallah A.
Publicado: (2018)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2021)

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021)

Myelodysplastic Syndrome in Hemodialysis Patients
por: Ayari, Hamza, et al.
Publicado: (2019)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics
por: Mees, Isaline, et al.
Publicado: (2023)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Hereditary Predispositions to Myelodysplastic Syndrome
por: Bannon, Sarah A., et al.
Publicado: (2016)

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Genetic basis of myelodysplastic syndromes
por: OGAWA, Seishi
Publicado: (2020)

Myelodysplastic Syndrome: Diagnosis and Screening
por: Tria, Francisco P., et al.
Publicado: (2022)

The Mesenchymal Niche in Myelodysplastic Syndromes
por: Friedrich, Chloé, et al.
Publicado: (2022)

Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
por: Chung, Howard, et al.
Publicado: (2021)

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
por: Kontandreopoulou, Christina-Nefeli, et al.
Publicado: (2021)

Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Sweet Syndrome Associated with Myelodysplastic Syndrome—A Review of a Multidisciplinary Approach
por: Ferea, Cătălina Roxana, et al.
Publicado: (2023)

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Barakos, Georgios Petros, et al.
Publicado: (2022)

Myelodysplastic syndrome with genetic predisposition
por: Park, Meerim
Publicado: (2021)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jja7dp05bfq1280q9ctjqb119c